Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash from Operations: 2019-2025

Historic Cash from Operations for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to $3.2 million.

  • Keros Therapeutics' Cash from Operations rose 110.65% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.8 million, marking a year-over-year increase of 163.28%. This contributed to the annual value of -$160.9 million for FY2024, which is 29.20% down from last year.
  • Keros Therapeutics' Cash from Operations amounted to $3.2 million in Q3 2025, which was up 110.97% from -$29.6 million recorded in Q2 2025.
  • Keros Therapeutics' Cash from Operations' 5-year high stood at $161.2 million during Q1 2025, with a 5-year trough of -$46.0 million in Q4 2024.
  • In the last 3 years, Keros Therapeutics' Cash from Operations had a median value of -$30.8 million in 2023 and averaged -$13.7 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 2,299.09% in 2023, then spiked by 461.69% in 2025.
  • Quarterly analysis of 5 years shows Keros Therapeutics' Cash from Operations stood at -$19.6 million in 2021, then dropped by 9.60% to -$21.4 million in 2022, then fell by 18.73% to -$25.5 million in 2023, then plummeted by 80.71% to -$46.0 million in 2024, then soared by 110.65% to $3.2 million in 2025.
  • Its Cash from Operations stands at $3.2 million for Q3 2025, versus -$29.6 million for Q2 2025 and $161.2 million for Q1 2025.